PMID- 16012852
OWN - NLM
STAT- MEDLINE
DCOM- 20060118
LR  - 20181113
IS  - 0945-6317 (Print)
IS  - 0945-6317 (Linking)
VI  - 447
IP  - 4
DP  - 2005 Oct
TI  - Monocyte chemotactic S19 ribosomal protein dimer in atherosclerotic vascular 
      lesion.
PG  - 747-55
AB  - To elucidate the molecular mechanism inducing monocyte/macrophage infiltration in 
      the atherosclerotic lesion, we measured the monocyte chemotactic capacity in the 
      extracts of aortic lesions. Five out of seven extracts exhibited significant 
      chemotactic activities. Immunohistochemical examination with an anti-CD68 
      monoclonal antibody demonstrated that the five positive lesions possessed obvious 
      monocyte/macrophage infiltrations at the intima, whereas the two negative lesions 
      did so at significantly lower intensities. We subjected the chemotactic extracts 
      to immunological analyses to identify the monocyte chemoattractant in them. The 
      monocyte chemotactic capacities of all positive extracts were removed with 
      anti-S19 ribosomal protein (RP S19) antibody beads and antimonocyte 
      chemoattractant protein-1 (MCP-1) antibody beads. In three of the five extracts, 
      the anti-RP S19 antibody beads were more effective than the anti-MCP-1 antibody 
      beads for removal, while in the remaining two extracts, the opposite was 
      observed. A combined immunoabsorption with these beads depleted the monocyte 
      chemotactic capacity of a representative sample of each group. Consistently, the 
      chemotactic capacity of an apparently RP S19 dimer-predominant extract was 
      strongly inhibited by the presence of a C5a receptor antagonist. These results 
      suggest that the RP S19 dimer and MCP-1 play a major role in the 
      monocyte/macrophage infiltration of the atherosclerotic vascular lesion.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Molecular Pathology, Faculty of Medical and Pharmaceutical 
      Sciences, Kumamoto University, 2-2-1 Honjo, Kumamoto, 860-0811, Japan.
FAU - Tsurusaki, Shigeyuki
AU  - Tsurusaki S
FAU - Futa, Noriko
AU  - Futa N
FAU - Sakamoto, Tamami
AU  - Sakamoto T
FAU - Matsuda, Tomoko
AU  - Matsuda T
FAU - Nishino, Norikazu
AU  - Nishino N
FAU - Kunitomo, Ryuji
AU  - Kunitomo R
FAU - Kawasuji, Michio
AU  - Kawasuji M
FAU - Tokita, Kazutaka
AU  - Tokita K
FAU - Yamamoto, Tetsuro
AU  - Yamamoto T
LA  - eng
PT  - Journal Article
DEP - 20051019
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (C5AR1 protein, human)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Membrane Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptor, Anaphylatoxin C5a)
RN  - 0 (Receptors, Complement)
RN  - 0 (Ribosomal Proteins)
RN  - 0 (ribosomal protein S19)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology
MH  - Antibody Affinity
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - Chemokine CCL2/metabolism
MH  - Chemotaxis, Leukocyte/*physiology
MH  - Coronary Artery Disease/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunohistochemistry
MH  - Membrane Proteins/antagonists & inhibitors
MH  - Monocytes/metabolism/pathology
MH  - Peptide Fragments/immunology/*metabolism
MH  - Rabbits
MH  - Receptor, Anaphylatoxin C5a/metabolism
MH  - Receptors, Complement/antagonists & inhibitors
MH  - Ribosomal Proteins/*metabolism
EDAT- 2005/07/14 09:00
MHDA- 2006/01/19 09:00
CRDT- 2005/07/14 09:00
PHST- 2004/09/17 00:00 [received]
PHST- 2005/04/27 00:00 [accepted]
PHST- 2005/07/14 09:00 [pubmed]
PHST- 2006/01/19 09:00 [medline]
PHST- 2005/07/14 09:00 [entrez]
AID - 10.1007/s00428-005-0012-5 [doi]
PST - ppublish
SO  - Virchows Arch. 2005 Oct;447(4):747-55. doi: 10.1007/s00428-005-0012-5. Epub 2005 
      Oct 19.